Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial

Background: Closed-loop (CL) systems direct insulin delivery based on continuous glucose monitor (CGM) sensor values. CGM accuracy varies with sensor life, being least accurate on day 1 of sensor insertion. We evaluated the effect of sensor life (enhanced Enlite, Medtronic MiniMed, Northridge, CA) on overnight CL. Methods: In an open-label, randomized, 2-period, inpatient crossover pilot study, 12 adolescents on insulin pump (age 16.7 ± 1.9 years; HbA1c 66 ± 10 mmol/mol) attended a clinical research facility on 2 overnight occasions. In random order, participants received CL on day 1 or on day 3-4 after sensor insertion. During both periods, glucose was automatically controlled by a model predictive control algorithm informed by sensor glucose. Plasma glucose was measured every 30 to 60 min. Results: During overnight CL (22:30 to 07:30), the proportion of time with plasma glucose readings in the target range (3.9-8.0 mmol/l, primary endpoint) when initiated on day 1 of sensor insertion vs day 3-4 were comparable (58 ± 32% day 1 vs 56 ± 36% day 3-4; P = .34), and there were no significant differences between interventions in terms of mean plasma glucose (P = .26), percentage time above 8.0 mmol/l (P = .49), and time spent below 3.9 mmol/l (P = .93). Sensor accuracy varied with sensor life (mean absolute relative difference 19.8 ± 15.0% on day 1 and 13.7 ± 10.2% on day 3 to 4). Sensor glucose tended to under-read plasma glucose inflating benefits of CL on glucose control. Conclusions: In spite of differences in sensor accuracy, overnight CL glucose control informed by sensor glucose on day 1 or day 3-4 after sensor insertion was comparable. The model predictive controller appears to mitigate against sensor inaccuracies.

[1]  Howard Zisser,et al.  Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. , 2012, Diabetes technology & therapeutics.

[2]  Roman Hovorka,et al.  Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. , 2016, The New England journal of medicine.

[3]  R. Hovorka Artificial Pancreas Project at Cambridge 2013 , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[4]  J. Jansen,et al.  Influence of inflammatory cells and serum on the performance of implantable glucose sensors. , 2001, Journal of biomedical materials research.

[5]  Claudio Cobelli,et al.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[6]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[7]  J. Hans DeVries,et al.  Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison. , 2013, Diabetes technology & therapeutics.

[8]  Ahmad Haidar,et al.  Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[9]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[10]  J K Mader,et al.  Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions , 2014, Diabetes, obesity & metabolism.

[11]  Peter Calhoun,et al.  Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes. , 2013, Diabetes technology & therapeutics.

[12]  Roman Hovorka,et al.  Closed-loop insulin delivery: from bench to clinical practice , 2011, Nature Reviews Endocrinology.

[13]  G. S. Wilson,et al.  Protein interactions with subcutaneously implanted biosensors. , 2006, Biomaterials.

[14]  Ben Feldman,et al.  Metabolic Biofouling of Glucose Sensors in Vivo: Role of Tissue Microhemorrhages , 2011, Journal of diabetes science and technology.

[15]  Ronald Brazg,et al.  Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. , 2014, Diabetes technology & therapeutics.

[16]  Lotty Hooft,et al.  Continuous glucose monitoring systems for type 1 diabetes mellitus. , 2012, The Cochrane database of systematic reviews.

[17]  David Rodbard,et al.  Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. , 2016, Diabetes technology & therapeutics.

[18]  Malgorzata E. Wilinska,et al.  Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial , 2015, Diabetes Care.

[19]  B. Wayne Bequette,et al.  Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis , 2015, Diabetes Care.

[20]  J. Hans DeVries,et al.  Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects. , 2016, Diabetes technology & therapeutics.

[21]  E. Atlas,et al.  Night glucose control with MD‐Logic artificial pancreas in home setting: a single blind, randomized crossover trial—interim analysis , 2014, Pediatric diabetes.

[22]  D. Klonoff,et al.  Threshold-based insulin-pump interruption for reduction of hypoglycemia. , 2013, The New England journal of medicine.

[23]  George Dailey,et al.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. , 2010, The New England journal of medicine.

[24]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[25]  Janet M. Allen,et al.  Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength , 2014, BMJ Open Diabetes Research and Care.